Question 1

What is Alnylam Pharmaceuticals's P/E ratio?

Accepted Answer

Alnylam Pharmaceuticals (ALNY) P/E ratio is 63.9× as of July 22, 2026. The ratio is calculated by dividing market capitalisation by trailing twelve-month earnings (net income), using USD-normalised financials (IAS 21 exchange-rate translation for non-USD reporters).

Question 2

How is the P/E ratio calculated?

Accepted Answer

P/E = Share Price ÷ Trailing Twelve-Month (TTM) Diluted EPS, or equivalently Market Capitalisation ÷ TTM Net Income. All inputs are sourced from audited GAAP/IFRS filings and translated to USD using period-end exchange rates so the multiple is comparable across companies and currencies.

Question 3

What is the P/E ratio?

Accepted Answer

The price-to-earnings (P/E) ratio, also called the earnings multiple, measures how much investors pay per dollar of a company's trailing twelve-month (TTM) earnings. It is calculated as share price ÷ TTM diluted EPS (equivalent to market capitalisation ÷ TTM net income). A higher P/E implies the market is pricing in stronger future earnings growth or lower risk; a lower P/E can signal slower expected growth, higher risk, or potential undervaluation.

Question 4

What is a good P/E ratio for Alnylam Pharmaceuticals?

Accepted Answer

There is no universal "good" P/E. As a rule of thumb, the S&P 500 has historically averaged a P/E in the mid-to-high teens; mature, slow-growth businesses commonly trade in the 10–18× range, while high-growth or asset-light companies often trade at 25–50×+. What matters is the comparison to sector peers and to the company's own historical range. For Alnylam Pharmaceuticals specifically, the relevant sector benchmark is the current sector median of 24.2×.

Question 5

Is Alnylam Pharmaceuticals's P/E ratio high or low?

Accepted Answer

Alnylam Pharmaceuticals's P/E ratio of 63.9× is below its own 5-year average of 539.9× and above the sector median of 24.2×. That places the current reading at the 0th percentile of its 10-year history. A higher multiple usually reflects stronger expected growth, lower perceived risk, or higher returns on capital; a lower multiple reflects the opposite.

Question 6

What is Alnylam Pharmaceuticals's historical P/E ratio range?

Accepted Answer

In the available daily series, Alnylam Pharmaceuticals (ALNY) P/E ratio has ranged from a low of 63.9× in 2026 to a high of 1492.1× in 2025. The 5-year average is 539.9× and the 5-year median is 167.6×.

Question 7

What was Alnylam Pharmaceuticals's P/E ratio in 2025?

Accepted Answer

Alnylam Pharmaceuticals (ALNY) P/E ratio at the end of 2025 was 167.6×. Annual values reflect the multiple on the last trading day of each calendar year, using the trailing twelve-month earnings figure available at that date.

Question 8

Why does Alnylam Pharmaceuticals's P/E ratio change over time?

Accepted Answer

Valuation multiples move with two inputs: the numerator (market capitalisation, which tracks the share price) and the denominator (earnings). Share-price changes — driven by interest rates, earnings expectations, risk appetite, and broader market sentiment — typically dominate short-term moves, while changes in the underlying fundamental drive the longer-term trend. As a result, the ratio can rise during stock-price rallies even if the business itself has not become more valuable, and fall during sell-offs even when fundamentals are improving.


2025	$52.6B	$314M	167.6×	—	Dec 31, 2025
2024	$30.3B	-$278M	—	—	Dec 31, 2024
2023	$24B	-$440M	—	—	Dec 31, 2023
2022	$29.3B	-$1.13B	—	—	Dec 31, 2022
2021	$20.3B	-$853M	—	—	Dec 31, 2021
2020	$15.1B	-$858M	—	—	Dec 31, 2020
2019	$12.9B	-$886M	—	—	Dec 31, 2019
2018	$7.37B	-$761M	—	—	Dec 31, 2018
2017	$12.2B	-$491M	—	—	Dec 31, 2017
2016	$3.21B	-$410M	—	—	Dec 31, 2016
2015	$7.99B	-$290M	—	—	Dec 31, 2015
2014	$7.46B	-$360M	—	—	Dec 31, 2014
2013	$4.05B	-$89.2M	—	—	Dec 31, 2013
2012	$946M	-$106M	—	—	Dec 31, 2012
2011	$377M	-$57.6M	—	—	Dec 31, 2011
2010	$416M	-$43.5M	—	—	Dec 31, 2010
2009	$738M	-$47.6M	—	—	Dec 31, 2009
2008	$1.02B	-$26.2M	—	—	Dec 31, 2008
2007	$1.18B	-$85.5M	—	—	Dec 31, 2007
2006	$800M	-$34.6M	—	—	Dec 31, 2006
2005	$401M	-$42.9M	—	—	Dec 31, 2005
2004	$153M	-$32.7M	—	—	Dec 31, 2004
2003	$9.95M	-$17.9M	—	—	Dec 31, 2003


Medtronic (MDT)	22.2×
McKesson (MCK)	22.2×
Illumina (ILMN)	21.7×
ResMed (RMD)	21.6×
GE HealthCare (GEHC)	21.6×
Pfizer (PFE)	21.1×
Quest Diagnostics (DGX)	21.1×
Henry Schein (HSIC)	21.0×
AptarGroup (ATR)	20.9×
IQVIA (IQV)	20.7×
Biogen (BIIB)	19.7×
Zoetis (ZTS)	18.9×
Gilead Sciences (GILD)	18.8×
Humana (HUM)	18.5×
Regeneron Pharmaceuticals (REGN)	18.2×
Bristol-Myers Squibb (BMY)	17.0×
Elevance Health (ELV)	17.0×
HCA Healthcare (HCA)	15.8×
AstraZeneca (AZN)	14.7×
DaVita (DVA)	13.3×
Incyte (INCY)	13.1×
Cigna (CI)	11.1×
Novo Nordisk (NVO)	8.6×
Solventum (SOLV)	7.9×
Universal Health Services (UHS)	7.2×

P/E Ratio for Alnylam Pharmaceuticals (ALNY) 2025-2026

P/E Ratio daily chart for Alnylam Pharmaceuticals (ALNY)

Historical P/E Ratio for Alnylam Pharmaceuticals (ALNY) from 2003 to 2025

About P/E Ratio at Alnylam Pharmaceuticals (ALNY)

Alnylam Pharmaceuticals P/E Ratio by Year

Alnylam Pharmaceuticals P/E Ratio 2025: 167.6×

Sector peers by P/E Ratio — chart

Sector peers by P/E Ratio — table

Frequently asked questions

Alnylam Pharmaceuticals (ALNY) Key Financials